Find Out if You Potentially Qualify for a Financial Reward by filling out the form.
(1) the design of SYFOVRE’s clinical trials was insufficient to identify incidents of retinal vasculitis in patients receiving SYFOVRE injections; (2) as a result, the commercial adoption of SYFOVRE was subject to significant, unknown risk factors; and (3) therefore, defendants’ statements about the Company’s business, operations, and prospects lacked a reasonable basis.
In order to be included in the lawsuit, you must have incurred a loss on shares of , either: A) purchased or acquired during the class period listed above, if applicable; or B) pursuant to the Initial Public Offering (IPO) of , if applicable.
If you suffered a loss in during the relevant time frame, or pursuant to ’s IPO if listed above, you have until October 02, 2023 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.